Total Payments
$1,898
2023 Payments
$116.96
Companies
2
Transactions
14
Payment Breakdown by Category
Research$1,708 (90.0%)
Food & Beverage$190.36 (10.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,708 | 12 | 90.0% |
| Food and Beverage | $190.36 | 2 | 10.0% |
Payments by Type
Research
$1,708
12 transactions
General
$190.36
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,708 | 12 | $0 (2022) |
| Seagen Inc. | $190.36 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $116.96 | 1 | Seagen Inc. ($116.96) |
| 2022 | $1,781 | 13 | ABBVIE INC. ($1,708) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $116.96 | General |
| 12/10/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $73.40 | General |
| 06/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $494.74 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $174.13 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $88.47 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $68.81 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $31.94 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/02/2022 | ABBVIE INC. | — | — | In-kind items and services | $31.94 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/01/2022 | ABBVIE INC. | — | — | In-kind items and services | $221.87 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/01/2022 | ABBVIE INC. | — | — | In-kind items and services | $88.47 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/01/2022 | ABBVIE INC. | — | — | In-kind items and services | $83.61 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 06/01/2022 | ABBVIE INC. | — | — | In-kind items and services | $36.86 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 05/31/2022 | ABBVIE INC. | — | — | In-kind items and services | $221.87 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
| 05/31/2022 | ABBVIE INC. | — | — | In-kind items and services | $165.18 | Research |
| Study: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ABBVIE INC. | $1,708 | 12 |
About Dr. Lianna Marks, MD
Dr. Lianna Marks, MD is a Pediatrics healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2011. The National Provider Identifier (NPI) number assigned to this provider is 1982998126.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lianna Marks, MD has received a total of $1,898 in payments from pharmaceutical and medical device companies, with $116.96 received in 2023. These payments were reported across 14 transactions from 2 companies. The most common payment nature is "" ($1,708).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatrics, Pediatric Hematology-Oncology
- Location Palo Alto, CA
- Active Since 06/06/2011
- Last Updated 04/16/2024
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1982998126
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Palo Alto
Carlos Milla, Md, MD
Pediatrics — Payments: $135,086
Pediatrics $135,086
Paul Grimm, Md, MD
Pediatrics — Payments: $115,205
Pediatrics $115,205
Janene Fuerch, Md, MD
Pediatrics — Payments: $106,632
Pediatrics $106,632
Jennifer Frankovich, Md, MD
Pediatrics — Payments: $99,067
Pediatrics $99,067
Crystal Mackall, Md, MD
Pediatrics — Payments: $56,852
Pediatrics $56,852
Jennifer O'malley, Md, Phd, MD, PHD
Pediatrics — Payments: $46,160
Pediatrics $46,160